Get access to our best features

Get access to our best features

Published 2 years ago

Five questions around Biogen in wake of the new Alzheimer's drug data

Summary by Ground News

Biogen Inc. has spent much of the past year shedding assets following the disastrous rollout of its first Alzheimer's disease drug. Now, a new Alzheimer's drug could turn things around and allow the Cambridge company to plan for growth again. Positive topline data from a new drug called lecanemab, which Japanese drugmaker Eisai Inc. largely developed with Biogen as its partner, has sent Biogen's shares skyrocketing.

0 Articles

0 Articles

All

Left

Center

Right

The Business Journals

Five questions around Biogen in wake of the new Alzheimer's drug data

Biogen has spent much of the year shedding assets following the disastrous rollout of its first Alzheimer's disease drug. Will its new Alzheimer's drug stop that decline?

2 years ago·United States

Read Full Article

Five Questions Around Biogen in Wake of the New Alzheimer's Drug Data

Five questions around Biogen in wake of the new Alzheimer’s drug data

2 years ago·Boston, United States

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year

Stories disproportionately reported by the Left or the Right

Ground News Article Assistant

Not enough coverage to generate an Article Assistant.

Coverage Details

Total News Sources0

Leaning Left1Leaning Right0Center1Last Updated2 years agoBias Distribution

50% Left, 50% Center

Bias Distribution

50% of the sources lean Left, 50% of the sources are Center

50% Center

NBC Boston

The Business Journals

Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Sources are mostly out of (0)

Similar News Topics

Stories disproportionately reported by the Left or the Right

Similar News Topics

Trending Topics

Donate Privacy Policy Manage Cookies Terms and Conditions

© 2024 Snapwise Inc.